leisure time -WSS

leisure time

author：leisure time 2025-09-14 11:44:09 - browse：38255

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： ProMED sees offers of support, but its future remains unclear

Wikipedia

entertainment

WSS

Testing for cancer recurrence creates a new limbo for patients

Biden's order seeks to regulate AI risk without stifling innovation

Testing for cancer recurrence creates a new limbo for patients

Majority of Americans think Trump's Ga. election interference case is serious: POLL

WHO may add ‘noma' to its list of neglected tropical diseases

Cancer drug shortages' outsize impact on ovarian cancer patients

explore

leisure time

Wikipedia

Sports medicine is finally prioritizing gender equality

Cassava reveals details — and problems — with Alzheimer's study

Walensky prepares to leave CDC — and Congress — behind

Clinical trials must include more disabled people

ChatGPT in medicine: STAT answers readers' burning questions

Biden's order seeks to regulate AI risk without stifling innovation

Alkermes shareholders re

Emergency medicine has repudiated 'excited delirium.' Now what?

Medical leaders decry Supreme Court decision on affirmative action

The pain doctors face in trying to build their families

explore

ProMED sees offers of support, but its future remains unclear

CDC recommends rationing of RSV shot due to shortages

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Evacuations in place as 3 wildfires burn in eastern Washington state

WHO may add ‘noma' to its list of neglected tropical diseases

Readout Newsletter: What happened with Sarepta's Duchenne data

Wikipedia

entertainment

Wikipedia

knowledge